These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 36012327)

  • 1. Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways.
    Piaserico S; Orlando G; Messina F
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review.
    Mehta H; Narang T; Dogra S; Handa S; Hatwal J; Batta A
    Vasc Health Risk Manag; 2024; 20():215-229. PubMed ID: 38745849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment.
    Hu SC; Lan CE
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29065479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiometabolic comorbidities and the approach to patients with psoriasis.
    Gisondi P; Girolomoni G
    Actas Dermosifiliogr; 2009 Dec; 100 Suppl 2():14-21. PubMed ID: 20096157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Psoriasis and cardiovascular disease].
    Torres T; Sales R; Vasconcelos C; Selores M
    Acta Med Port; 2013; 26(5):601-7. PubMed ID: 24192101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time.
    Merzel Šabović EK; Starbek Zorko M; Janić M
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiometabolic risk in psoriasis: differential effects of biologic agents.
    Kaplan MJ
    Vasc Health Risk Manag; 2008; 4(6):1229-35. PubMed ID: 19337536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psoriasis and cardiovascular disorders.
    Frieder J; Ryan C
    G Ital Dermatol Venereol; 2016 Dec; 151(6):678-693. PubMed ID: 27627099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The concept of psoriasis as a systemic inflammation: implications for disease management.
    Reich K
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():3-11. PubMed ID: 22356630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.
    Caiazzo G; Fabbrocini G; Di Caprio R; Raimondo A; Scala E; Balato N; Balato A
    Front Immunol; 2018; 9():1668. PubMed ID: 30150978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-17 Links Inflammatory Cross-Talks Between Comorbid Psoriasis and Atherosclerosis.
    Wang Y; Zang J; Liu C; Yan Z; Shi D
    Front Immunol; 2022; 13():835671. PubMed ID: 35514987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
    Hugh J; Van Voorhees AS; Nijhawan RI; Bagel J; Lebwohl M; Blauvelt A; Hsu S; Weinberg JM
    J Am Acad Dermatol; 2014 Jan; 70(1):168-77. PubMed ID: 24184141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients.
    Cao H; Su S; Yang Q; Le Y; Chen L; Hu M; Guo X; Zheng J; Li X; Yu Y
    Lipids Health Dis; 2021 Feb; 20(1):16. PubMed ID: 33602246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-17 as a factor linking the pathogenesis of psoriasis with metabolic disorders.
    Owczarczyk-Saczonek A; Placek W
    Int J Dermatol; 2017 Mar; 56(3):260-268. PubMed ID: 27696392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriasis: the visible killer.
    Torres T; Bettencourt N
    Rev Port Cardiol; 2014 Feb; 33(2):95-9. PubMed ID: 24525359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity.
    Boehncke WH; Boehncke S; Tobin AM; Kirby B
    Exp Dermatol; 2011 Apr; 20(4):303-7. PubMed ID: 21410760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compounds of psoriasis with obesity and overweight.
    Owczarczyk-Saczonek A; Placek W
    Postepy Hig Med Dosw (Online); 2017 Aug; 71(1):761-772. PubMed ID: 28894050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis.
    Egeberg A; Gisondi P; Carrascosa JM; Warren RB; Mrowietz U
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1695-1706. PubMed ID: 32022950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis.
    Kimball AB; Szapary P; Mrowietz U; Reich K; Langley RG; You Y; Hsu MC; Yeilding N; Rader DJ; Mehta NN
    J Am Acad Dermatol; 2012 Jul; 67(1):76-85. PubMed ID: 22018756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic markers for cardiovascular disease in psoriasis: the missing piece.
    Torres T; Chiricozzi A; Chimenti S; Saraceno R
    Mol Diagn Ther; 2014 Feb; 18(1):93-5. PubMed ID: 24078347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.